RxDoctor Payments Data

George Sutton, MD

Family Medicine · Mobile, ALNPI 1407802283

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AstraZeneca at 39.7% of the total. Reporting peaked in 2021 at $124 and has fallen 73.5% since, to $33 in 2023. That places this record below the midpoint for family medicine clinicians in AL, where the typical reported total is $638.

$248in general payments, 2019–2025

Across 13 payments — averaging $19.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$98
  • Sunovion Pharmaceuticals Inc.$60
  • Otsuka America Pharmaceutical, Inc.$19
  • Avanir Pharmaceuticals, Inc.$16
  • Johnson & Johnson$14
  • Sumitomo Pharma America, Inc.$14
  • plus $26 from 2 others

What the payments were for

  • Food & beverage$248100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$248 in reported general payments places this provider in the 35th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama →

Medicare billing

Part B allowed, 2024
$75,282
Medicare patients
262
Services billed
847

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban349$129,797
IngrezzaValbenazine Tosylate30$111,574
AustedoDeutetrabenazine19$45,509
CreonLipase/Protease/Amylase20$30,454
TivicayDolutegravir Sodium20$28,867
DescovyEmtricitabine/Tenofov Alafenam16$26,296
XareltoRivaroxaban73$25,952
RexultiBrexpiprazole23$23,729
JardianceEmpagliflozin62$23,688
TradjentaLinagliptin77$21,791
OzempicSemaglutide18$18,486
GemtesaVibegron42$14,809
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$13,223
Memantine Hcl214$9,953
Mesalamine17$9,528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$14$25,95273 claims
Otsuka America Pharmaceutical, Inc.Rexulti$19$23,72923 claims
Sumitomo Pharma America, Inc.Gemtesa$14$14,80942 claims
AstraZenecaLokelma$98$3,33914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Mobile

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →